Endo Health Solutions is extending its makeover with a bolt-on deal, trading $105 million up front for NuPathe to get its hands on the migraine patch Zecuity.
NuPathe crossed the regulatory finish line with FDA approval of its migraine patch, Zecuity, overcoming the agency's concerns about the battery-powered delivery system that prompted a denial from U.S. regulators in 2011.
Hunkering down ahead of a January 17 PDUFA date for its experimental migraine patch, NuPathe says it will lay off half of its staff as it conserves resources, raises cash and looks for a partner to help commercialize the product in the event of an approval.
The FDA has handed NuPathe a complete response letter detailing demands for new information on its experimental migraine patch, Zelrix (NP101). But even after scrambling to try and reassure investors
Conshohocken, PA-based NuPathe has cuts its IPO price to just $10 a share, the company announced today. NuPathe was hoping to raise between $14 and $16 per share for a total of $75 million. The
Conshohocken, PA-based NuPathe, which is developing a transdermal patch version of the popular migraine treatment Imitrex, has set the terms of its proposed IPO. NuPathe will offer 5 million common
Yet another biotech company has announced plans to file an IPO. Conshohocken, PA-based NuPathe, which is developing a transdermal patch to treat migraines, hopes to raise $86.3 million, according to
NuPathe announced positive results from a key late-stage study of Zelrix, a transdermal patch designed for the treatment of acute migraine. The multi-center trial involved 530 adults. Data from the